Samsun Ceftriaxone Sodium Hydrate Injection 1 Gram

Adult administration

For adults and children over 12 years old, administer 1 to 2 g (potency) of ceftriaxone intravenously or intramuscularly once daily. In infections caused by pathogens showing severe illness or moderate sensitivity, the dosage can be increased to 4 g (potency) once daily. For the treatment of gonorrhea, a single intramuscular injection of 250 mg (potency) is recommended. For the prevention of infections before and after surgery, a single dose of 1 to 2 g (potency) should be administered 30 to 90 minutes before surgery.

Child administration

For newborns (up to 14 days old), administer 20 to 50 mg per kg (potency) once daily, not exceeding 50 mg (potency). For infants and children (from 15 days to 12 years old), administer 20 mg per kg

This medication should not be mixed or administered simultaneously with solutions or medications containing calcium. In particular, it should not be used in conjunction with calcium-containing solutions in newborns up to 28 days old, as this can cause precipitation and lead to serious side effects. Patients with hypersensitivity to this medication or those allergic to cephalosporin or penicillin antibiotics should not receive it. Additionally, this medication containing lidocaine should not be administered intravenously, and it should not be used in premature infants or newborns with bilirubin binding disorders. Close monitoring of the patient's condition is necessary during administration for allergic reactions or impaired kidney and liver functions. During administration, side effects such as rashes, diarrhea, headache, dizziness, blood abnormalities, and elevated liver enzymes may occur; if any abnormal symptoms arise, immediate notification to medical personnel is necessary. If severe allergic reactions or shock symptoms occur, administration must be stopped immediately, and emergency treatment should be sought. The risk of renal toxicity may increase when this medication is combined with other antibiotics, so caution is advised, and it should always be administered separately from calcium. Pregnant or nursing women should make prudent judgments if the use of this medication is deemed necessary. It is advisable not to use this medication in newborns, particularly premature infants, due to the risk of bilirubin encephalopathy. Elderly patients are at a higher risk of side effects due to decreased bodily functions, requiring dose adjustment and monitoring. Regular liver and kidney function tests and blood tests are recommended during the administration of this medication. Furthermore, this medication may cause dizziness, affecting driving or operation of machinery; therefore, caution is needed. During storage, the prepared solution should be used as soon as possible, as it may change color depending on storage temperature and time, but this does not affect its efficacy.

Serious side effects

Urticaria, severe swelling (edema), cold sweat, difficulty breathing, chest tightness, anaphylaxis and anaphylactic-like reactions, severe allergic reaction, severe skin adverse reactions (such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), encephalopathy, acute renal failure, neurological disorders (including headache, confusion, seizures), jaundice, generalized severe lethargy, severe edema with elevated blood pressure or urination abnormalities, urine

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• elevated liver enzymes
• headache
• dizziness
• bronchospasm
• loose stools

This medication should be stored in a sealed container to prevent exposure to air, and it is recommended to keep it at room temperature between 1 to 30 degrees Celsius. This will help maintain the medication's efficacy and prevent deterioration.

Appearance

A colorless transparent vial containing a white to pale yellow powder

Package unit

10 vials/box [(1 vial x 10)]